iPS cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy
Cell types differentiated from induced pluripotent stem cells (iPSCs) are frequently arrested in their development program, more closely resembling a fetal rather than an adult phenotype, potentially limiting their utility for downstream clinical applications. The fetal phenotype of iPSC‐derived den...
Autori principali: | Horton, C, Davies, TJ, Lahiri, P, Sachamitr, P, Fairchild, PJ |
---|---|
Natura: | Journal article |
Lingua: | English |
Pubblicazione: |
Wiley
2019
|
Documenti analoghi
Documenti analoghi
-
Cross presentation of antigen by dendritic cells: mechanisms and implications for immunotherapy.
di: Sachamitr, P, et al.
Pubblicazione: (2012) -
Towards the rational design of a next-generation dendritic cell vaccine for cancer immunotherapy
di: Bravo, M, et al.
Pubblicazione: (2021) -
Directed differentiation of human induced pluripotent stem cells into dendritic cells displaying tolerogenic properties and resembling the CD141+ subset
di: Sachamitr, P, et al.
Pubblicazione: (2018) -
Enhancement of tolerogenic or immunostimulatory potential of dendritic cells for therapeutic goals
di: Hanif, Javanmard Khameneh
Pubblicazione: (2011) -
Enhancement of tolerogenic or immunostimulatory potential of dendritic cells for therapeutic goals.
di: Hanif Javanmard Khameneh
Pubblicazione: (2014)